Trial Profile
Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours a pilot study (IONIC-1)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary) ; Nivolumab (Primary)
- Indications Gastric cancer; Lung cancer; Nasopharyngeal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms IONIC-1
- Sponsors Noxopharm
- 06 Jun 2023 Results (n=11) assessing the safety and preliminary efficacy of NOX66 in combination with nivolumab in patients with advanced cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 24 Apr 2023 According to a Noxopharm media release, this trial is taking place at six sites in the Sydney area and regional NSW. The current patient cohort is being treated with a Veyonda dose of 1800mg, however the slow recruitment rate remains a challenge. Preliminary data from the IONIC trial will be published online in conjunction with the upcoming American Society of Clinical Oncology (ASCO) annual meeting taking place from 2-6 June 2023.
- 11 Nov 2021 Status changed from planning to recruiting.